

The Transcriptional Regulator AlgR Controls Cyanide Production in *Pseudomonas aeruginosa*

Alexander J. Carterson,¹ Lisa A. Morici,¹ Debra W. Jackson,¹ Anders Frisk,¹ Stephen E. Lizewski,¹ Ryan Jupiter,¹ Kendra Simpson,¹ Daniel A. Kunz,² Scott H. Davis,³ Jill R. Schurr,⁴ Daniel J. Hassett,⁵ and Michael J. Schurr^{1*}

Department of Microbiology and Immunology, Program in Molecular Pathogenesis and Immunity, Louisiana Center for Lung Biology and Immunotherapy,¹ and Department of Pediatrics,³ Tulane University Health Sciences Center, and Department of Genetics, Louisiana State University Health Sciences Center,⁴ New Orleans, Louisiana; Division of Biochemistry and Molecular Biology, Department of Biological Sciences, University of North Texas, Denton, Texas²; and Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati College of Medicine, Cincinnati, Ohio⁵

Received 27 April 2004/Accepted 14 July 2004

***Pseudomonas aeruginosa* is an opportunistic pathogen that causes chronic lung infections in cystic fibrosis (CF) patients. One characteristic of *P. aeruginosa* CF isolates is the overproduction of the exopolysaccharide alginate, controlled by AlgR. Transcriptional profiling analyses comparing mucoid *P. aeruginosa* strains to their isogenic *algR* deletion strains showed that the transcription of cyanide-synthesizing genes (*hcnAB*) was ~3-fold lower in the *algR* mutants. S1 nuclease protection assays corroborated these findings, indicating that AlgR activates *hcnA* transcription in mucoid *P. aeruginosa*. Quantification of hydrogen cyanide (HCN) production from laboratory isolates revealed that mucoid laboratory strains made sevenfold more HCN than their nonmucoid parental strains. In addition, comparison of laboratory and clinically derived nonmucoid strains revealed that HCN was fivefold higher in the nonmucoid CF isolates. Moreover, the average amount of cyanide produced by mucoid clinical isolates was 4.7 ± 0.85 μmol of HCN/mg of protein versus 2.4 ± 0.40 μmol of HCN/mg of protein for nonmucoid strains from a survey conducted with 41 *P. aeruginosa* CF isolates from 24 patients. Our data indicate that (i) mucoid *P. aeruginosa* regardless of their origin (laboratory or clinically derived) produce more cyanide than their nonmucoid counterparts, (ii) AlgR regulates HCN production in *P. aeruginosa*, and (iii) *P. aeruginosa* CF isolates are more hypercyanogenic than nonmucoid laboratory strains. Taken together, cyanide production may be a relevant virulence factor in CF lung disease, the production of which is regulated, in part, by AlgR.**

Pseudomonas aeruginosa is an opportunistic pulmonary pathogen of patients with cystic fibrosis (CF), where it is the major cause of morbidity and mortality. *P. aeruginosa* is able to persist and exacerbate damage in the lungs that ultimately results in respiratory failure. One unique feature of *P. aeruginosa* CF isolates is overproduction of the exopolysaccharide alginate that phenotypically results in a mucoid colony morphology (23). The first committed step for alginate production is transcriptional activation of the *algD* gene (12), an event that requires the AlgR regulator and the alternative sigma factor AlgU (AlgT) (11, 14, 26, 34, 35, 38, 39, 46). Mucoidy is also associated with the chronic phase of CF airway disease where the bacteria acquire increased resistance to various antibiotics and phagocytic cells. Furthermore, increasing evidence suggests that *P. aeruginosa* may be in a microaerophilic or anaerobic microenvironment trapped within biofilms in the thick mucus lining the airways of CF patients (48, 55, 59). Under such conditions, the organisms are able to produce alginate and maintain mucoidy (25, 48, 56, 59).

It has long been recognized that *P. aeruginosa* generates poisonous cyanide as a secondary metabolite (7). Hydrogen

cyanide (HCN) is produced from glycine (7, 54) in a poorly understood oxidative reaction catalyzed by HCN synthase (8, 9, 53) whose expression requires the *las/rhl* tandem of the intercellular signaling process known as quorum sensing (43, 44). HCN is not produced when the organism is grown under strict anaerobic conditions when supplied nitrate as a terminal electron acceptor (7) but rather occurs optimally at low oxygen tensions (~5%) during the transition from exponential to stationary phase when bacteria are at high cell densities and fully capable of quorum sensing (6, 10, 43, 44). An early report (22) describing the detection of HCN in *P. aeruginosa*-infected wounds from burn patients gave cause to believe that the cyanogenic properties of the organism may be a contributing factor in its pathogenicity. Further support for this hypothesis stems from recent studies demonstrating that a mutant defective in *hcnC* had a strongly reduced ability to kill the nematode *Caenorhabditis elegans* in an experimental infection model (18). In addition, recent transcriptional profiling analyses revealed that mucoid *P. aeruginosa* actively transcribes *hcnA*, encoding HCN synthase (16), further suggesting that cyanide production may be an important virulence factor.

The present study extends the recent work (29) examining the molecular basis underlying the ability of AlgR to control virulence in *P. aeruginosa*. Through the use of Affymetrix Gene Chip technology, we previously identified many potential genes under AlgR control, one of which was *hcnA* (30). Here, we

* Corresponding author. Mailing address: Department of Microbiology and Immunology, Tulane University Health Sciences Center, 1430 Tulane Ave., New Orleans, LA 70112-2699. Phone: (504) 988-4607. Fax: (504) 588-5144. E-mail: mschurr@tulane.edu.

TABLE 1. Strains used in this study

<i>P. aeruginosa</i>	Genotype	Phenotype ^a	Reference or source
PAO1	Wild type	NM	27
PAO381	<i>leu</i>	NM	17
PDO300	<i>mucA2</i>	M	32
PDR300	<i>mucA2 ΔalgR</i>	NM	This study
PAO6857	<i>mucB::Tc^r</i>	M	47
PAR6857	<i>mucB::Tc^r ΔalgR</i>	NM	This study
PA0568	<i>mucA2</i>	M	17
PAR568	<i>mucA2 ΔalgR</i>	NM	This study
FRD1	<i>mucA</i>	M	21
FRD1R	<i>mucA algR::Sm^r</i>	NM	31
TUMC92	Clinical isolate	NM	This study
TUMC-92R	<i>ΔalgR</i>	NM	This study
TUMC197	Clinical isolate	NM	This study
TUMC-197R	<i>ΔalgR</i>	NM	This study
<i>Escherichia coli</i> DH-5α			Invitrogen

^a M, mucoid; NM, nonmucoid.

show that (i) mucoid *P. aeruginosa* strains produce copious amounts of HCN, (ii) AlgR regulates this process, and (iii) HCN production in clinical CF isolates is significantly elevated over that of laboratory strains.

MATERIALS AND METHODS

Bacterial strains, plasmids, and growth conditions. The *P. aeruginosa* strains used in this study are listed in Table 1. *P. aeruginosa* strains PAO6857 (*mucB::Tc^r*), PAO568 (*mucA2*), PAR568 (*mucA2 ΔalgR*), and PAR6857 (*mucB::Tc^r ΔalgR*) were grown in modified *Pseudomonas* isolation media (20 g of peptone/liter, 7 mM MgCl₂, 59 mM K₂SO₄, 2% glycerol, pH 7.0) under microaerophilic conditions for S1 nuclease protection assays. Overnight cultures were diluted 1:100 in 500-ml aeration flasks capped with rubber stoppers and then placed at 37°C with slow shaking at 100 rpm for microaerophilic growth conditions. These cultures were grown to an optical density at 600 nm (OD₆₀₀) of 0.4. The plasmid used for *algR* complementation was pCMR7 (*algR⁺*) (38). Routine overnight cultures were grown in Luria-Bertani broth at 37°C in a rotary shaker incubator. Carbenicillin (300 μg/ml) was supplemented as needed for plasmid maintenance and genetic manipulations.

DNA manipulations. The *algR* gene was deleted from strains as previously described (30). Briefly, an *algR* deletion plasmid (pRKO442 [*ΔalgR*]) was introduced into clinical and laboratory *P. aeruginosa* strains by triparental conjugation (28), and double recombinants were obtained by selection of carbenicillin-sensitive and sucrose-resistant colonies (15). Deletion of *algR* was confirmed by PCR with oligonucleotide primers ArgHF (5'-ATATATGAGCTCGGACCTGTCCG ACCTGTTCC-3') and HemCR (5'-ATATATGAGCTCGGCTGGCGTAGGT GTTCGAG-3') and Southern blot (data not shown) and Western blot analysis with anti-AlgR (see Fig. 2A and 4B) (13).

Western blot analysis of AlgR. *P. aeruginosa* strains were grown aerobically in Luria-Bertani broth at 37°C overnight. The bacteria were collected by centrifugation and resuspended in 50 mM Tris-HCl (pH 8.0)–150 mM NaCl and lysed by sonication. Total protein concentrations were quantified by the Bradford protein assay (Bio-Rad). Cell extracts (30 μg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 5 to 20% polyacrylamide gradient gels and transferred to a polyvinylidene difluoride membrane (GE Osmonics). The membranes were probed using a 1:2,000 dilution of anti-AlgR mouse monoclonal antibody (13) followed by a 1:2,000 dilution of horseradish peroxidase-conjugated goat anti-mouse monoclonal antibody and the signal was detected using the Opti-4CN substrate kit (Bio-Rad).

Qualitative gaseous HCN production assay of *P. aeruginosa* strains. An initial screen of *P. aeruginosa* CF isolates was performed by testing qualitatively for gaseous HCN production using a modified method of Castric and Castric (5). Whatman filter paper strips were soaked with 5 mg each of copper(II) ethyl acetoacetate and 4,4'-methylenebis-(*N,N*-dimethylaniline) dissolved in 2.5 ml of chloroform and allowed to air dry. The strips were placed in the lids of L agar plates streaked with *P. aeruginosa* CF clinical isolates and incubated inverted overnight at 37°C. Relative HCN production was indicated by a change in the color of the strips from white to blue. As a control, L agar plates with no bacteria

and the qualitative assay strip were incubated in the same incubator with CF isolates on different plates at the same time.

Quantitative HCN production assay of *P. aeruginosa* strains. Twelve nonmucoid and mucoid clinical isolates from the same patient were quantified for HCN production. In addition, 17 isolates from 12 other patients were randomly selected for HCN production. A significantly modified protocol of Gallagher and Manoil was used to measure HCN (18). Laboratory and clinical *P. aeruginosa* isolates were grown on 8.5-cm-diameter plates of *Pseudomonas* isolation agar for 16 to 24 h at 37°C in triplicate and then enclosed without the lid in sealed chambers containing 1 ml of 4 M NaOH. After a 4-h incubation at 30°C, the NaOH was diluted to 0.09 M with H₂O. Next, the samples were further diluted in 0.09 M NaOH to bring the cyanide concentration to within the linear detection range (0 to 15 μM potassium cyanide [KCN]). Cyanide levels were quantified by comparison with KCN standards dissolved in 0.09 M NaOH as follows. Samples (210 μl) were mixed with 700 μl of a 1:1 mixture of 0.1 M *o*-dinitrobenzene in ethylene-glycol monomethyl ether and 0.2 M *p*-nitrobenzaldehyde in ethylene-glycol monomethyl ether. After a 30-min incubation at 22°C, the OD₅₇₈ was measured as previously described (18). Total protein was determined for each strain by collecting bacteria grown on an agar plate and resuspending the cells in 5 ml of 0.85% NaCl. After centrifugation (10,500 × g), the cells were lysed and protein precipitated in 5% trichloroacetic acid (37). Protein pellets were resuspended in 1 ml of 50 mM KH₂PO₄ and the total amount of protein was determined by Bradford assay (Bio-Rad). Cyanide production is expressed as the ratio between the total amount (micromoles) of HCN and the total amount (milligrams) of bacterial protein recovered from cells grown on a petri dish.

S1 nuclease protection assays. RNA for S1 nuclease protection assays was isolated from PAO6857 (*mucB::Tc^r*), PAR6857 (*PAO6857 ΔalgR*), PAO568 (*mucA2*), and PAR568 (*PAO568 ΔalgR*) grown to stationary phase using CsCl as previously described (35). An S1 nuclease protection assay was performed as previously described using 100 μg of RNA with the following modifications (35). The 519-bp region of the *hcnA* promoter ranging from -495 to +24 (numbering relative to translational start site) was cloned into M13mp18. Single-stranded phages were isolated and used as the template for the uniformly labeled ([α-³²P]dCTP; NEN DuPont) single-stranded DNA probe. The probe was digested using BglI and purified on a 5% polyacrylamide gel. The probe was hybridized to 100 μg of RNA from the above strains and treated with S1 nuclease, and the products were separated on a sequencing gel adjacent to a sequencing ladder generated using the same oligonucleotide, *hcnA*primex (5'-GTGTTGACGAC GTTCAAGAAGGTGCAT-3'), as the probe.

AlgR gel mobility shift assay. Binding of AlgR to the *hcnA* promoter region was examined using native AlgR, purified as previously described (38). A 99-bp DNA fragment containing the *hcnA* promoter (-495 to -396 in relation to the translational start site) was excised from pCR*hcnA* (*hcnA* promoter in pCR2.1) by EcoRI and end-labeled with [γ-³²P]ATP (6,000 Ci/mmol; NEN Dupont) using T4 polynucleotide kinase (Invitrogen, Carlsbad, Calif.). The probe was purified by passing through a G-25 Sephadex microspin column (Amersham Pharmacia Biotech, Inc., Piscataway, N.J.). Binding reactions were carried out as described previously with some modifications (38). Briefly, the probe was mixed with 100 ng of AlgR containing 25 mM Tris-HCl (pH 8.0), 0.5 mM dithiothreitol, 20 mM KCl, 0.5 mM EDTA, 5% glycerol, 10 μg of salmon sperm DNA, and an additional 0.25 μg of pUC12 per ml as nonspecific competitor DNA. Competition assays were performed by the addition of unlabeled pCR*hcnA*, to determine the specificity of AlgR. After incubation for 10 min at room temperature, the samples were separated by electrophoresis on a 5% native polyacrylamide gel with Sharp's buffer (6.7 mM Tris-HCl [pH 8.0], 3.3 mM sodium acetate, 1.0 mM EDTA) used as a running buffer for approximately 1.5 h at 30 mA. Subsequently, the gel was dried and bands were visualized by autoradiography.

RESULTS

Cyanide production is elevated in mucoid *P. aeruginosa*. Analysis of the transcriptional profile comparing *mucA2* and *mucB::Tc^r* mucoid *P. aeruginosa* strains to their isogenic *algR* deletion strains showed that *hcnA* transcription was ~3-fold lower in the *algR* mutant strains (unpublished data). These results are consistent with those of Firoved and Deretic, who reported that *hcnA* transcription is sixfold greater in the *mucA22* mucoid strain PAO578I than in its isogenic *algU* mutant (16). Since AlgR is required for alginate production (11) and controlled by AlgU (35), we postulated that AlgR may be




FIG. 1. Cyanide production is controlled by AlgR and elevated in laboratory mucoid *P. aeruginosa*. Quantification of HCN (micromoles per milligram of protein) produced in 4 h from nonmucoid parent strains PAO1 and PAO381 (horizontally lined bars), mucoid derivative strains PAO568, PAO6857, and PDO300 (solid bars), subsequent isogenic *algR* deletion strains PAR568, PAR6857, and PDR300 (vertically lined bars), and complemented *algR* deletion strains PDR300+*algR*, PAR6857+*algR*, and PAR568+*algR* (open bars). All of the parent mucoid strains produced elevated levels of HCN compared to their relative *algR* deletion counterparts. *, $P < 0.05$ when compared to the parent strain, as determined by unpaired t test.

activating *hcnA* transcription in mucoid *P. aeruginosa* bacteria. Therefore, cyanide was measured directly in mucoid and nonmucoid laboratory strains of PAO1 and PAO381. The nonmucoid laboratory strains PAO1 and PAO381 produced an average of 0.49 μmol of cyanide/mg of protein. In contrast, the *mucA* mucoid derivatives of these strains, PDO300 and PAO568, respectively, each produced approximately seven times the amount of cyanide (Fig. 1). In addition, PAO6857 (*mucB::Tc^r*) produced 3.3-fold more cyanide than PAO1 (Fig. 1). Taken together, these results indicate that mucoid derivatives of *P. aeruginosa* produce more cyanide than their nonmucoid parental strains.

Mucoid *P. aeruginosa* requires AlgR for complete *hcnA* expression and cyanide production. To determine if AlgR plays a role in a *mucA2* derivative of *P. aeruginosa*, *algR* was deleted from *P. aeruginosa* strains PAO568 and PDO300 (Fig. 2A). An S1 nuclease protection assay performed on the *hcnA* promoter from PAO568 and its *algR* deletion strain PAR568 revealed that transcription from *hcnA* promoter T1 was elevated in PAO568 compared to the same promoter in PAR568 (Fig. 2B). HCN production was then quantified in the mucoid *mucA2* strains PDO300 and PAO568 and their respective *algR* deletion strains. This comparison revealed that the mucoid *mucA* parental strain produced an average of 1.5-fold more cyanide than the *algR* mutants (Fig. 1). Moreover, overexpression of *algR* in *trans* in the *algR* deletion strains restored cyanide production (Fig. 1).

To determine if AlgR affected *hcnA* transcription in a *mucB* mucoid *P. aeruginosa* strain, *algR* was deleted in

PAO6857 (*mucB::Tc^r*) to generate the strain PAR6857 (*mucB::Tc^r Δ algR*) (Fig. 2A). An S1 nuclease protection analysis was performed on the *hcnA* promoter by using total RNA from these strains grown microaerophilically and revealed AlgR activated the T1 and T2 promoters of *hcnA* (Fig. 2B and C). Moreover HCN determinations revealed that PAO6857 produced 1.9-fold more HCN per milligram of protein than its *algR* deletion strain PAR6857 (Fig. 1). This result is consistent with the transcriptional profile analysis of the same strain and its *algR* deletion mutant that indicated *hcnA* is activated threefold by AlgR. Taken together, these results suggest that AlgR activates cyanide production by ~ 2 -fold in mucoid laboratory strains of *P. aeruginosa*, irrespective of the nature of the mutation (*mucA*, *mucB*) conferring the mucoid phenotype.

AlgR binds to the *hcnA* promoter region. Since *hcnA* transcription is *algR* dependent and there is an AlgR binding site within the *hcnA* promoter (-410 to -402 ; GAACgACGG, where the lowercase "g" represents a departure from the reverse and complement of the *algD/algC* consensus AlgR binding sequence [30]), we tested the ability of purified AlgR to bind the *hcnA* promoter region in an in vitro gel mobility shift assay. AlgR caused a shift in mobility compared to the probe alone, indicating that AlgR is capable of binding to the *hcnA* promoter region (Fig. 3). The addition of nonradioactive *hcnA* (specific competitor) reduced the amount of probe shifted by AlgR in a dose-dependent manner, indicating specificity of AlgR for the *hcnA* promoter region. Additionally, nonradioactive pUC12 was added as a nonspecific competitor to ensure that competition was not due to nonspecific AlgR DNA binding. These results provide in vitro evidence that AlgR binds specifically to the *hcnA* promoter DNA.

Clinical *P. aeruginosa* CF isolates produce elevated cyanide levels. To determine the prevalence of cyanide production among *P. aeruginosa* CF isolates, we performed a qualitative HCN production assay on 167 clinical *P. aeruginosa* isolates from 103 CF patients. This assay showed that 74% of all isolates examined produced HCN (data not shown). Furthermore, 83% of CF patients from the Tulane University Medical Center were found to carry at least one positive *P. aeruginosa* HCN-producing strain. To confirm these results, the amount of cyanide produced by 41 separate clinical CF *P. aeruginosa* isolates from 24 CF patients was quantified. The average amount of cyanide produced by all 41 strains was 3.5 μmol of cyanide/mg of protein, indicating that the majority of CF patients surveyed harbored *P. aeruginosa* strains that constitutively produced HCN when tested in vitro. When HCN production by both mucoid and nonmucoid isolates from 12 patients was compared, the amount of cyanide detected averaged 4.4 ± 1.1 and 2.5 ± 0.5 μmol of HCN/mg of protein, respectively. We then examined eight mucoid strains from additional patients for whom there were no nonmucoid isolates and found an average amount of 5.2 ± 1.2 μmol of HCN/mg of protein produced. We also examined nine nonmucoid strains from patients that did not carry mucoid isolates and determined that these strains produced an average of 1.36 ± 0.6 μmol of HCN/mg of protein. Overall, the amount of cyanide produced by mucoid *P. aeruginosa* CF isolates was approximately twice as high as that of nonmucoid CF isolates (Fig.




FIG. 2. AlgR controls the expression of *hcnA* in mucoid *P. aeruginosa*. S1 nuclease protection assay of the *hcnA* promoter region. A. Western blot analysis of PAO1, PDO300 (*mucA2*), PDR300 (*mucA2 ΔalgR*), PAO6857 (*mucB::Tc^r*), and PAR6857 (*mucB::Tc^r ΔalgR*) using anti-AlgR 3H-9 confirmed the deletion of the 29-kDa transcriptional regulator, AlgR, in strains PAR6857, PDR300, and PAR568. MW, molecular weight. B. Mapped transcriptional start sites T1 and T2 of the mucoid strains PAO6857 and PAO568 and their *algR* deletion strains PAR6857 and PAR568. C. Schematic of the *hcnA* promoter sequence. T1 and T2, mapped transcriptional start sites (indicated with arrows); ANR box, ANR binding site; *lux* α and *lux* β, LasR and RhlR binding sites.

4A). This is in agreement with the results we obtained with the mucoid laboratory strains of *P. aeruginosa*.

AlgR activates cyanide production in mucoid CF clinical isolates and represses HCN production in nonmucoid CF isolates. In order to assess the role of AlgR in clinical CF isolates on HCN production, *algR* was deleted from the well-characterized mucoid CF isolate FRD1 (Fig. 4B). The amount of cyanide produced by the mucoid CF isolate FRD1 was compared with its isogenic *algR* mutant which revealed that FRD1 *algR* produced only 1.05 μmol of HCN/mg of protein, an amount eightfold lower than that for FRD1 (Fig. 4C). Interestingly, among CF clinical isolates, there were nonmucoid isolates that produced copious amounts of HCN (for example, TUMC92, 5.5 μmol of HCN/mg of protein, and TUMC197, 6.25 μmol of HCN/mg of protein) despite their nonmucoid phenotype. Thus, to ascertain the relevance of AlgR in regulating HCN production in nonmucoid clinical CF isolates, isogenic *algR* mutants were constructed for the nonmucoid hypercyanogenic clinical isolates TUMC92 and TUMC197 (Fig.

4B) and cyanide production was measured. We observed a threefold increase in cyanide production in the clinical *algR* mutant TUMC-197R and a 1.8-fold increase in cyanide production from the *algR* clinical isolate TUMC-92R (Fig. 4C). These results are consistent with our observation that AlgR repressed HCN production in the wild-type nonmucoid *P. aeruginosa* strain PAO1 (30). These results provide strong evidence that AlgR activates cyanide production in mucoid CF clinical isolates and represses its production in nonmucoid isolates.

DISCUSSION

The effects of HCN have been examined on many cell types (2, 24, 41). In these studies, HCN exposure resulted in neuronal necrosis (41) and inhibition of metalloenzymes including cytochrome *c* oxidase (49). One report of KCN exposure to the immortalized epithelial lung A549 cells resulted in double-stranded DNA breaks below 0.5 Mbp, indicating that endog-




FIG. 3. AlgR binds specifically to the *hcnA* promoter. Competitive gel mobility shift assay of AlgR on the *hcnA* promoter region. The probe-alone lane contains only labeled *hcnA* promoter (99 bp, -495 to -396 in relation to the translational start site) from plasmid pCR*hcnA*. All other lanes contain the same amount of labeled *hcnA* promoter plus 100 ng of purified AlgR. For the specific competitor, the given micrograms of undigested pCR*hcnA* was added to the DNA/AlgR mix. For the nonspecific competitor, the given micrograms of undigested pUC12 was added to the DNA/AlgR mix.

enous nuclease activity was induced in a dose-dependent manner after KCN exposures (50). These data suggest that A549 cells exposed to >1 mM KCN may undergo necrosis. Cell death via necrosis results in increased inflammation and infiltration of polymorphonuclear leukocytes to the site of infection. Excess inflammation due to migration of polymorphonuclear leukocytes and lung necrosis are pathological hallmarks of CF airway infection (1).

In this study, we quantified the amount of HCN produced by mucoid and nonmucoid laboratory and CF isolates of *P. aeruginosa* and showed that AlgR, a transcriptional regulator of alginate biosynthesis (11, 38–40) and twitching motility (51, 52), plays a central role in controlling HCN production. Although HCN-producing *P. aeruginosa* strains have been isolated from burn patients (22), the only evidence that HCN may be a virulence factor in *P. aeruginosa* stems from an experimental infection model utilizing *C. elegans* (18). Since at physiological pH and ambient temperatures and above, cyanide exists predominantly as volatile HCN gas, it is possible to envision that HCN generated by *P. aeruginosa* CF strains could diffuse into the environment through exhaled breath with no deleterious effects. However, a recent report (19) describing the detection of cyanide in CF patient sputum could be interpreted as indicating that cyanide, in the form of either gaseous HCN or soluble cyanide (CN⁻), remains in the thick mucus layer harboring *P. aeruginosa* biofilms, thus being potentially available for diffusion into surrounding lung epithelial cells.

The conditions in *P. aeruginosa*-infected lung tissue appear to be optimal for cyanide production given that the thick CF mucus (48, 55, 59) provides an ideal environment for the growth of cells to high cell densities as a biofilm under microaerophilic conditions, processes controlled in part by quorum sensing (43, 44). Interestingly, there are two reported promoters for the *hcnA* gene, T1, controlled by quorum-sensing regulators alone, and T2, which appears to rely on a synergistic action of LasR, RhlR, and ANR (Fig. 2C) (43). Five regulatory proteins have been identified for the *hcnA* promoter: GacA (45), ANR (45, 62), LasR, RhlR (43), and RsmA (42). The global regulator GacA positively controls HCN synthesis as well as other secondary metabolites and exoenzymes (45). *P. aeruginosa* *gacA* or *anr* mutants produce very little




FIG. 4. Mucoid clinical CF isolates produce more HCN than nonmucoid isolates. A. Mean quantification of HCN produced in 4 h from 20 mucoid and 21 nonmucoid CF clinical isolates. Mucoid isolates produce approximately twofold more HCN than nonmucoid isolates. *, $P < 0.05$, as determined by unpaired *t* test. B. Western blot analysis of clinical isolates FRD1, TUMC92, and TUMC197 and their *algR* deletion strains FRD1R (*algR*::Sm^r), TUMC-92R (Δ *algR*), and TUMC-197R (Δ *algR*) using anti-AlgR. C. Quantification of HCN produced in 4 h from clinical isolates TUMC197 and TUMC92 and their *algR* deletion strains, TUMC-197R and TUMC-92R, and from the mucoid CF isolate FRD1 and its nonmucoid *algR* strain FRD1R. Solid bar, mucoid strain; horizontally lined bars, nonmucoid strains; vertically lined bars, *algR* deletion strains. *, $P < 0.05$, as determined by unpaired *t* test. **, $P < 0.01$, as determined by unpaired *t* test.

HCN (45, 62). One positive regulator of anaerobic respiration, ANR, is required for anaerobic growth of *P. aeruginosa* (58). LasR and RhlR are quorum-sensing regulators required for transcription of the *hcnA* promoter (43). RsmA (regulator of




FIG. 5. Schematic representing possible mechanisms for AlgR activation. Transcriptional profiling experiments have shown that AlgR is capable of repressing transcription of *hcnA* and other genes (30). We have shown that AlgR activates *hcnA* transcription and HCN production in mucoid *P. aeruginosa*. Mutations in *mucA* (4, 34), *mucB* (33), or *mucD* (3) result in release of the alternative sigma factor AlgU, resulting in increased transcription of *algR* (35). AlgZ/FimS has been shown to be a repressor of alginate production (60) and an activator of twitching motility (51, 52). However phosphorylation does not play a role in AlgR activation of the alginate system (31) but is necessary for activation of twitching motility (52). These results imply that there may be more than one way to activate AlgR in *P. aeruginosa*. The *hcnA* promoter is the only known example where AlgR acts as a repressor in the nonmucoid state and as an activator in the mucoid phenotype. Rounded star, repressor AlgR; pointed star, activated AlgR.

secondary metabolites) functions as a pleiotropic posttranscriptional regulator of HCN synthesis directly and also indirectly by negatively regulating the amounts of quorum sensing *N*-acylhomoserine lactones (42). Our data provide strong evidence that AlgR also regulates *hcnA* transcription by affecting both T1 and T2 promoters, indicating that AlgR and LasR and/or RhlR and ANR coordinately regulate these promoters. Moreover, we have discovered through transcriptional profiling experiments that there are other genes (*hemN*, *PAI557*, and *arcD*) of the AlgR regulon that are coregulated by AlgR and ANR (30). Further studies are needed to elucidate the mechanism by which these transcriptional regulators may potentially interact.

Under anaerobic growth conditions, *P. aeruginosa* is able to produce alginate and maintain its production (25, 48, 56, 59). Our survey of both laboratory and CF isolates demonstrated that mucoid *P. aeruginosa* produced more HCN than nonmucoid strains. These findings are consistent with the fact that environmental conditions favoring cyanogenesis by *P. aeruginosa* also favor alginate production (25, 48, 55, 59). Alginate is considered to be a major virulence factor in the CF lung (23) with the first committed step of biosynthesis being the transcription of *algD*, which is activated in mucoid *P. aeruginosa* (12). Transcription of *algD* requires AlgR as well as the alternative sigma factor AlgU (AlgT) (11, 14, 26, 34, 35, 38, 39, 46). AlgR is currently known as a transcriptional activator of the *algD* (11, 38–40) and *algC* (61) promoters and is required for type IV pilus function (51, 52). The switch from the nonmucoid to the mucoid phenotype in *P. aeruginosa* is known to involve mutations in *mucA* or *mucB*, resulting in activation of AlgU (AlgT) (20, 33, 34, 36, 57) and subsequently AlgR (35).

Recently, it was shown that AlgR is capable of acting as a repressor of transcription on the *hcnA* promoter and HCN production in the nonmucoid strain PAO1 (30). Results from

our present study indicate that AlgR is an activator of *hcnA* transcription and HCN production in both mucoid laboratory and CF clinical isolates. Taken together, these results strongly suggest that AlgR is capable of switching from a repressor in the nonmucoid phenotype to an activator in mucoid *P. aeruginosa* (Fig. 5). This interpretation is consistent with results demonstrating that the switch from nonmucoid to mucoid phenotypes involving mutations in *mucA* or *mucB* results in activation of AlgU (AlgT) (20, 33, 34, 36, 57) and also AlgR (35). The resultant activation of AlgR may be due to increased levels or posttranslational modifications; however, our data do not discern between these two possible mechanisms for AlgR activation of cyanide production. There is evidence that phosphorylation of AlgR is required for twitching motility (52), yet the kinase for AlgR has not been identified. The protein involved in the ability of AlgR to switch from a repressor to an activator of twitching motility may be AlgZ/FimS, as an insertional inactivation of *algZ/fimS* results in the loss of twitching motility (50). We have preliminary evidence indicating that AlgZ/FimS is also involved in activation of AlgR in mucoid *P. aeruginosa*, consistent with the findings on AlgZ/FimS in regards to the twitching motility phenotype.

Because cyanide could have extremely potent detrimental effects on respiratory epithelial cells, novel strategies for the future treatment of CF airway disease may involve inhibitors of both the quorum sensing and AlgR regulatory cascades, both of which are required for cyanide biosynthesis in *P. aeruginosa*.

ACKNOWLEDGMENTS

This work was supported by LEQSF (1999-02) RD-A-42 and HEF (2000-05)–06 grants from the State of Louisiana Board of Regents and by National Institutes of Health (NIH) grant RO1-AI050812-01A2 (to M.J.S.), National Science Foundation grant MCB 012680 (to D.A.K.), NIH grant R01-40541, and the Cystic Fibrosis Foundation (D.J.H.). The cost of the *P. aeruginosa* GeneChips was defrayed in part by subsidy grant no. 024 from Cystic Fibrosis Foundation Therapeutics, Inc., to M.J.S.

Microarray equipment and technical support were supplied by the GeneChip Bioinformatics core at the Louisiana State University Health Sciences Center.

REFERENCES

- Boat, T. F., M. J. Welsh, and A. L. Beaudet. 1989. Cystic fibrosis, p. 2649–2680. In C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle (ed.), *The metabolic basis of inherited disease*, 6th ed., vol. II. McGraw-Hill, New York, N.Y.
- Borron, S. W., and F. J. Baud. 1996. Acute cyanide poisoning: clinical spectrum, diagnosis and treatment. *Arch. Toxicol. Ind. Hyg.* **47**:307–322.
- Boucher, J. C., J. M. Martinez-Salazar, M. J. Schurr, M. H. Mudd, H. Yu, and V. Deretic. 1996. Two distinct loci affecting conversion to mucoidy in *Pseudomonas aeruginosa* in cystic fibrosis encode homologs of the serine protease HtrA. *J. Bacteriol.* **178**:511–523.
- Boucher, J. C., H. Yu, M. H. Mudd, and V. Deretic. 1997. Mucoid *Pseudomonas aeruginosa* in cystic fibrosis: characterization of *muc* mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection. *Infect. Immun.* **65**:3838–3846.
- Castric, K. F., and P. A. Castric. 1983. Method for detection of cyanogenic bacteria. *Appl. Environ. Microbiol.* **45**:701–702.
- Castric, P. A. 1983. Hydrogen cyanide production by *Pseudomonas aeruginosa* at reduced oxygen levels. *Can. J. Microbiol.* **29**:1344–1349.
- Castric, P. A. 1975. Hydrogen cyanide, a secondary metabolite of *Pseudomonas aeruginosa*. *Can. J. Microbiol.* **21**:613–618.
- Castric, P. A. 1994. Influence of oxygen on the *Pseudomonas aeruginosa* hydrogen cyanide synthase. *Curr. Microbiol.* **29**:19–21.
- Castric, P. A. 1981. The metabolism of hydrogen cyanide by bacteria, p. 233–261. In B. Vennesland, E. E. Conn, C. J. Knowles, J. Westley, and F. Wissing (ed.), *Cyanide in biology*. Academic Press Ltd., London, United Kingdom.
- Castric, P. A., R. F. Ebert, and K. F. Castric. 1979. The relationship between

- growth phase and cyanogenesis in *Pseudomonas aeruginosa*. *Curr. Microbiol.* **2**:287–292.
11. Deretic, V., R. Dikshit, W. M. Konyecsni, A. M. Chakrabarty, and T. K. Misra. 1989. The *algR* gene, which regulates mucoidy in *Pseudomonas aeruginosa*, belongs to a class of environmentally responsive genes. *J. Bacteriol.* **171**:1278–1283.
 12. Deretic, V., J. F. Gill, and A. M. Chakrabarty. 1987. Gene *algD* coding for GDPmannose dehydrogenase is transcriptionally activated in mucoid *Pseudomonas aeruginosa*. *J. Bacteriol.* **169**:351–358.
 13. Deretic, V., N. S. Hibler, and S. C. Holt. 1992. Immunocytochemical analysis of AlgP (H_p1), a histonelike element participating in control of mucoidy in *Pseudomonas aeruginosa*. *J. Bacteriol.* **174**:824–831.
 14. DeVries, C. A., and D. E. Ohman. 1994. Mucoid-to-nonmucoid conversion in alginate-producing *Pseudomonas aeruginosa* often results from spontaneous mutations in *algT*, encoding a putative alternate sigma factor, and shows evidence for autoregulation. *J. Bacteriol.* **176**:6677–6687.
 15. Donnesberg, M. S., and J. B. Kaper. 1991. Construction of an *eae* deletion mutant of enteropathogenic *Escherichia coli* by using a positive selection suicide vector. *Infect. Immun.* **59**:4310–4317.
 16. Firoved, A. M., and V. Deretic. 2003. Microarray analysis of global gene expression in mucoid *Pseudomonas aeruginosa*. *J. Bacteriol.* **185**:1071–1081.
 17. Fyfe, J. A. M., and J. R. W. Govan. 1980. Alginate synthesis in mucoid *Pseudomonas aeruginosa*: a chromosomal locus involved in control. *J. Gen. Microbiol.* **119**:443–450.
 18. Gallagher, L. A., and C. Manoil. 2001. *Pseudomonas aeruginosa* PAO1 Kills *Caenorhabditis elegans* by cyanide poisoning. *J. Bacteriol.* **183**:6207–6214.
 19. Gallagher, L. A., C. Manoil, and J. L. Burns. 2003. Presented at *Pseudomonas* 2003, Quebec City, Canada.
 20. Goldberg, J. B., W. L. Gorman, J. Flynn, and D. E. Ohman. 1993. A mutation in *algN* permits *trans* activation of alginate production by *algT* in *Pseudomonas* species. *J. Bacteriol.* **175**:1303–1308.
 21. Goldberg, J. B., and D. E. Ohman. 1984. Cloning and expression in *Pseudomonas aeruginosa* of a gene involved in the production of alginate. *J. Bacteriol.* **158**:1115–1121.
 22. Goldfarb, W. B., and H. Margraf. 1967. Cyanide production by *Pseudomonas aeruginosa*. *Ann. Surg.* **165**:104–110.
 23. Govan, J. R. W., and V. Deretic. 1995. Microbial pathogenesis in cystic fibrosis: mucoid *Pseudomonas aeruginosa* and *Burkholderia cepacia*. *Microbiol. Rev.* **60**:539–574.
 24. Greer, J. J., and E. Jo. 1995. Effects of cyanide on neural mechanism controlling breathing in neonatal rat *in vivo*. *Neurotoxicology* **16**:211–215.
 25. Hassett, D. J. 1996. Anaerobic production of alginate by *Pseudomonas aeruginosa*: alginate restricts diffusion of oxygen. *J. Bacteriol.* **178**:7322–7325.
 26. Hershberger, C. D., R. W. Ye, M. R. Parsek, Z.-D. Xie, and A. M. Chakrabarty. 1995. The *algT* (*algU*) gene of *Pseudomonas aeruginosa*, a key regulator involved in alginate biosynthesis, encodes an alternative σ factor (σ^F). *Proc. Natl. Acad. Sci. USA* **92**:7941–7945.
 27. Holloway, B. W. 1955. Genetic recombination in *Pseudomonas aeruginosa*. *J. Gen. Microbiol.* **13**:572–581.
 28. Konyecsni, W. M., and V. Deretic. 1988. Broad-host-range plasmid and M13 bacteriophage-derived vectors for promoter analysis in *Escherichia coli* and *Pseudomonas aeruginosa*. *Gene* **74**:375–386.
 29. Lizewski, S. E., D. S. Lundberg, and M. J. Schurr. 2002. The transcriptional regulator AlgR is essential for *Pseudomonas aeruginosa* pathogenesis. *Infect. Immun.* **70**:6083–6093.
 30. Lizewski, S. E., J. R. Schurr, D. W. Jackson, A. Frisk, A. J. Carterson, and M. J. Schurr. 2004. Identification of AlgR-regulated genes in *Pseudomonas aeruginosa* by use of microarray analysis. *J. Bacteriol.* **186**:5672–5684.
 31. Ma, S., U. Selvaraj, D. E. Ohman, R. Quarless, D. J. Hassett, and D. J. Wozniak. 1998. Phosphorylation-independent activity of the response regulators AlgB and AlgR in promoting alginate biosynthesis in mucoid *Pseudomonas aeruginosa*. *J. Bacteriol.* **180**:956–968.
 32. Malhotra, S., L. A. Silo-Suh, K. Mathee, and D. E. Ohman. 2000. Proteome analysis of the effect of mucoid conversion on global protein expression in *Pseudomonas aeruginosa* strain PAO1 shows induction of the disulfide bond isomerase, DsbA. *J. Bacteriol.* **182**:6999–7006.
 33. Martin, D. W., M. J. Schurr, M. H. Mudd, and V. Deretic. 1993. Differentiation of *Pseudomonas aeruginosa* into the alginate-producing form: inactivation of *mucB* causes conversion to mucoidy. *Mol. Microbiol.* **9**:497–506.
 34. Martin, D. W., M. J. Schurr, M. H. Mudd, J. R. W. Govan, B. W. Holloway, and V. Deretic. 1993. Mechanism of conversion to mucoidy in *Pseudomonas aeruginosa* infecting cystic fibrosis patients. *Proc. Natl. Acad. Sci. USA* **90**:8377–8381.
 35. Martin, D. W., M. J. Schurr, H. Yu, and V. Deretic. 1994. Analysis of promoters controlled by the putative sigma factor AlgU regulating conversion to mucoidy in *Pseudomonas aeruginosa*: relationship to stress response. *J. Bacteriol.* **176**:6688–6696.
 36. Mathee, K., C. J. McPherson, and D. E. Ohman. 1997. Posttranslational control of the *algT* (*algU*)-encoded σ^{22} for expression of the alginate regulon in *Pseudomonas aeruginosa* and localization of its antagonist proteins MucA and MucB (AlgN). *J. Bacteriol.* **179**:3711–3720.
 37. May, T. B., and A. M. Chakrabarty. 1994. Isolation and assay of *Pseudomonas aeruginosa* alginate. *Methods Enzymol.* **235**:295–304.
 38. Mohr, C. D., N. S. Hibler, and V. Deretic. 1991. AlgR, a response regulator controlling mucoidy in *Pseudomonas aeruginosa*, binds to the FUS sites of the *algD* promoter located unusually far upstream from the mRNA start site. *J. Bacteriol.* **173**:5136–5143.
 39. Mohr, C. D., J. H. J. Leveau, D. P. Krieg, N. S. Hibler, and V. Deretic. 1992. AlgR-binding sites within the *algD* promoter make up a set of inverted repeats separated by a large intervening segment of DNA. *J. Bacteriol.* **174**:6624–6633.
 40. Mohr, C. D., D. W. Martin, W. M. Konyecsni, J. R. Govan, S. Lory, and V. Deretic. 1990. Role of the far-upstream sites of the *algD* promoter and the *algR* and *rpoN* genes in environmental modulation of mucoidy in *Pseudomonas aeruginosa*. *J. Bacteriol.* **172**:6576–6580.
 41. Niquet, J., R. A. Baldwin, S. G. Allen, D. G. Fujikawa, and C. G. Wasterlain. 2003. Hypoxic neuronal necrosis: protein synthesis-independent activation of a cell death program. *Proc. Natl. Acad. Sci. USA* **100**:2825–2830.
 42. Pessi, G., and D. Haas. 2001. Dual control of hydrogen cyanide biosynthesis by the global activator GacA in *Pseudomonas aeruginosa* PAO1. *FEMS Microbiol. Lett.* **200**:73–78.
 43. Pessi, G., and D. Haas. 2000. Transcriptional control of the hydrogen cyanide biosynthetic genes *hcnABC* by the anaerobic regulator ANR and the quorum-sensing regulators LasR and RhIR in *Pseudomonas aeruginosa*. *J. Bacteriol.* **182**:6940–6949.
 44. Pessi, G., F. Williams, Z. Hindle, K. Heurlier, M. T. Holden, M. Camara, D. Haas, and P. Williams. 2001. The global posttranscriptional regulator RsmA modulates production of virulence determinants and *N*-acetylglucosamine lactones in *Pseudomonas aeruginosa*. *J. Bacteriol.* **183**:6676–6683.
 45. Reimmann, C., M. Beyeler, A. Latifi, H. Winteler, M. Foglino, A. Lazdunski, and D. Haas. 1997. The global activator GacA of *Pseudomonas aeruginosa* PAO positively controls the production of the autoinducer *N*-butyryl-homoserine lactone and the formation of the virulence factors pyocyanin, cyanide, and lipase. *Mol. Microbiol.* **24**:309–319.
 46. Schurr, M. J., D. W. Martin, M. H. Mudd, N. S. Hibler, J. C. Boucher, and V. Deretic. 1993. The *algD* promoter: regulation of alginate production by *Pseudomonas aeruginosa* in cystic fibrosis. *Cell. Mol. Biol. Res.* **39**:371–376.
 47. Schurr, M. J., H. Yu, J. M. Martinez-Salazar, J. C. Boucher, and V. Deretic. 1996. Control of AlgU, a member of the σ^E -like family of stress sigma factors, by the negative regulators MucA and MucB and *Pseudomonas aeruginosa* conversion to mucoidy in cystic fibrosis. *J. Bacteriol.* **178**:4997–5004.
 48. Singh, P. K., A. L. Schaefer, M. R. Parsek, T. O. Moninger, M. J. Welsh, and E. P. Greenberg. 2000. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. *Nature* **407**:762–764.
 49. Solomonson, L. P. 1981. Cyanide as a metabolic inhibitor, p. 11–28. *In* C. J. Knowles, J. Westley, J. Wissing, and F. Wissing (ed.), *Cyanide in biology*. Academic Press, London, United Kingdom.
 50. Vock, E. H., W. K. Lutz, P. Hormes, H. D. Hoffmann, and S. Vamvakas. 1998. Discrimination between genotoxicity and cytotoxicity in the induction of DNA double-strand breaks in cells treated with etoposide, melphalan, cisplatin, potassium cyanide, Triton X-100, and gamma-irradiation. *Mutat. Res.* **413**:83–94.
 51. Whitchurch, C. B., R. A. Alm, and J. S. Mattick. 1996. The alginate regulator AlgR and an associated sensor FimS are required for twitching motility in *Pseudomonas aeruginosa*. *Proc. Natl. Acad. Sci. USA* **93**:9839–9843.
 52. Whitchurch, C. B., T. E. Erova, J. A. Emery, J. L. Sargent, J. M. Harris, A. B. Semmler, M. D. Young, J. S. Mattick, and D. J. Wozniak. 2002. Phosphorylation of the *Pseudomonas aeruginosa* response regulator AlgR is essential for type IV fimbria-mediated twitching motility. *J. Bacteriol.* **184**:4544–4554.
 53. Wissing, F. 1983. Anaerobic column chromatography in the presence of detergents and its application to bacterial HCN-producing enzymes. *J. Microbiol. Methods* **1**:31–39.
 54. Wissing, F. 1974. Cyanide formation from oxidation of glycine by a *Pseudomonas* species. *J. Bacteriol.* **117**:1289–1294.
 55. Worlitzsch, D., R. Tarran, M. Ulrich, U. Schwab, A. Kekici, K. C. Meyer, P. Birrer, G. Bellon, J. Berger, T. Weiss, K. Botzenhart, J. R. Yankaskas, S. Randell, R. C. Boucher, and G. Doring. 2002. Effects of reduced mucus oxygen concentration in airway *Pseudomonas* infections of cystic fibrosis patients. *J. Clin. Investig.* **109**:317–325.
 56. Wyckoff, T. J., B. Thomas, D. J. Hassett, and D. J. Wozniak. 2002. Static growth of mucoid *Pseudomonas aeruginosa* selects for non-mucoid variants that have acquired flagellum-dependent motility. *Microbiology* **148**:3423–3430.
 57. Xie, Z. D., C. D. Hershberger, S. Shankar, R. W. Ye, and A. M. Chakrabarty. 1996. Sigma factor–anti-sigma factor interaction in alginate synthesis: inhibition of AlgT by MucA. *J. Bacteriol.* **178**:4990–4996.
 58. Ye, R. W., D. Haas, J. O. Ka, V. Krishnapillai, A. Zimmermann, C. Baird, and J. M. Tiedje. 1995. Anaerobic activation of the entire denitrification pathway in *Pseudomonas aeruginosa* requires Anr, an analog of Fnr. *J. Bacteriol.* **177**:3606–3609.
 59. Yoon, S. S., R. F. Hennigan, G. M. Hilliard, U. A. Ochsner, K. Parvatiyar, M. C. Kamani, H. L. Allen, T. R. DeKievit, P. R. Gardner, U. Schwab, J. J. Rowe, B. H. Iglewski, T. R. McDermott, R. P. Mason, D. J. Wozniak, R. E.

- Hancock, M. R. Parsek, T. L. Noah, R. C. Boucher, and D. J. Hassett. 2002. *Pseudomonas aeruginosa* anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis. *Dev. Cell* 3:593–603.
60. Yu, H., M. Mudd, J. C. Boucher, M. J. Schurr, and V. Deretic. 1997. Identification of the *algZ* gene upstream of the response regulator AlgR and its participation in control of alginate production in *Pseudomonas aeruginosa*. *J. Bacteriol.* 179:187–193.
61. Zielinski, N. A., A. M. Chakrabarty, and A. Berry. 1991. Characterization and regulation of the *Pseudomonas aeruginosa algC* gene encoding phosphomannomutase. *J. Biol. Chem.* 266:9754–9763.
62. Zimmermann, A., C. Reimmann, M. Galimand, and D. Haas. 1991. Anaerobic growth and cyanide synthesis of *Pseudomonas aeruginosa* depend on *anr*, a regulatory gene homologous with *fur* of *Escherichia coli*. *Mol. Microbiol.* 5:1483–1490.